Full Breakdown
U.S. Conditions Funding to Gavi on Thimerosal Removal
1/28/2026, 10:09:59 PM
U.S. Request for Thimerosal Phase-Out
The Trump administration has mandated that the global vaccine alliance Gavi phase out vaccines containing thimerosal, a mercury-based preservative, as a condition for future funding. This request, confirmed by both a U.S. official and a Gavi spokesperson, reflects the administration's broader efforts to influence global health policy. Thimerosal is primarily used in multi-dose vials to maintain vaccine stability, particularly in low- and middle-income countries, where such vials are more cost-effective and easier to distribute.
Background on Thimerosal and Vaccine Safety
Thimerosal has been a contentious topic, especially among anti-vaccine groups, including one founded by U.S. Health Secretary Robert F. Kennedy Jr. These groups have long claimed a link between thimerosal and autism, despite numerous studies conducted over decades that have found no compelling evidence to support these claims. The World Health Organization (WHO) has stated that the risks of vaccine-preventable diseases far outweigh any potential risks associated with thimerosal.
Implications of U.S. Funding Conditions
The U.S. government's request aims to align Gavi's vaccine policies with those of the U.S., Canada, and most European nations, where thimerosal has largely been phased out. The U.S. previously contributed approximately 13% of Gavi's funding, and the current request pertains to both the outstanding $300 million pledged by the Biden administration and any future funding. Gavi has indicated that any changes to its vaccine portfolio would require decisions from its board and input from scientific governance committees.
Criticism and Opposition
Critics argue that the U.S. conditions could jeopardize vaccination efforts in low-income countries, where thimerosal-containing vaccines are crucial for immunization campaigns. Gavi has emphasized that vaccine safety is its top priority and is in ongoing discussions with the U.S. government regarding the thimerosal issue. The WHO has reiterated that extensive research has shown thimerosal to be safe, particularly when compared to the risks of not vaccinating children against serious diseases.
Conflicting Reports & Gaps
While the U.S. has moved to stop using thimerosal in influenza vaccines, representing about 5% of flu shots, the broader implications of this policy shift remain unclear. The U.S. health department's recent withdrawal of its recommendation for hepatitis B vaccinations for newborns has also drawn criticism, highlighting ongoing debates about vaccine safety and public health policy.
Verbatim Quotes
“Until a plan for removal of thimerosal-containing vaccines is developed and the plan initiated, the United States will withhold future new funding,” — U.S. Department of Health and Human Services Official
“While we very much hope to find a pathway to welcoming the U.S. back as a donor, any decision related to Gavi’s portfolio would require a decision by Gavi’s board and input from preceding governance committees, which will be guided by scientific consensus,” — Gavi Spokesperson
“No compelling scientific evidence has been found to suggest that there is a risk, particularly when compared to the dangers of keeping children unprotected against deadly diseases, the WHO says.” — World Health Organization
This situation underscores the complexities of global health funding and the ongoing debates surrounding vaccine safety and public health initiatives.
